ASCO 2015 Highlights

Cost-Effectiveness in the New Comparative Effectiveness Landscape

ASCO Conference

September 2010, Vol 1, No 4

Moving Targets: Personalized Medicine and Targeted Therapies

Personalized Medicine

July/August 2010, Vol 1, No 3

Medicare, a Major P(l)ayer, Not Ready for New Payment Policy Evidence

July/August 2010, Vol 1, No 3

Direct-to-Consumer Genetics/Genomics: A “New Paradigm” in Providing Healthcare Information

Genomic Testing

July/August 2010, Vol 1, No 3

Clinical Trials: Understanding Cost, Coverage Implications

Clinical Trials

July/August 2010, Vol 1, No 3

How Will Costs Be Contained in the New Healthcare Environment?

Economics & Value

July/August 2010, Vol 1, No 3

Adherence to Colon Cancer Chemotherapy Guidelines Depends on Treatment Setting

Chemotherapy, Personalized Medicine

July/August 2010, Vol 1, No 3

Reasons for Breast Cancer Care Disparities Remain Unclear

Disparities in Oncology

July/August 2010, Vol 1, No 3

Comparative Effectiveness Research Will Help Guide Health Policy

Health Policy, Policies & Guidelines

July/August 2010, Vol 1, No 3

Pathway Compliance Reduces Drug, Nondrug Expenses

Pathways, Policies & Guidelines

July/August 2010, Vol 1, No 3

Evaluation of a regional payer-based pay-for-quality (P4Q)oncology program showed thatPathways programs can greatly reduce the cost of cancer care by slowingthe growth rate of both drug andnondrug expenses.

Page 324 of 330